Global Virtual Clinical Trials Market Growth, Size, Trends Analysis - By Study Design, By Indication, By Phase - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Virtual Clinical Trials Market Introduction and Overview

According to SPER market research, 'Global Virtual Clinical Trials Market Growth, Size, Trends Analysis - By Study Design, By Indication, By Phase - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Virtual Clinical Trials Market is predicted to reach 16.52 billion by 2034 with a CAGR of 5.95%.

Virtual clinical trials, also known as decentralised clinical trials or remote clinical trials, are a new approach to clinical research in which some or all of the trial procedures are carried out remotely using digital technologies and decentralised methodologies. This implies that participants can take part in the trial from the comfort of their own homes or other convenient locations, providing data, interacting with healthcare providers, and participating in study-related activities using digital devices and platforms.

Restraints: The rigorous laws and regulations are projected to stifle expansion in the worldwide virtual clinical trials market. The challenges and complexity associated with virtual clinical trials are another factor preventing the sector from expanding. There are various hurdles to virtual clinical trials, including data protection, regulatory compliance, and standard operating procedures. The privacy of patient data is a key problem.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Study Design, By Indication, By Phase

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

ICON, plc, Parexel International Corporation, IQVIA, Covance, PRA Health Sciences, LEO Innovation Lab, Medidata, Oracle, CRF Health Clinical Ink Medable, Inc.

Global Virtual Clinical Trials Market Segmentation:

By Study Design: Based on the Study Design, Global Virtual Clinical Trials Market is segmented as; Interventional, Observational, Expanded Access.

By Indication: Based on the Indication, Global Virtual Clinical Trials Market is segmented as; CNS, Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Infectious Disease, Oncology, Genitourinary, Ophthalmology, Others.

By Phase: Based on the Phase, Global Virtual Clinical Trials Market is segmented as; Phase I, Phase II, Phase III, Phase IV.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa

Product Code: HLCA25191

1.Introduction

1.1.Scope of the report
1.2.Market segment analysis

2.Research Methodology

2.1.Research data source
- 2.1.1.Secondary Data
- 2.1.2.Primary Data
- 2.1.3.SPERs internal database
- 2.1.4.Premium insight from KOLs
2.2.Market size estimation
- 2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

4.1.Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1.Drivers
- 4.1.2.Restraints
- 4.1.3.Opportunities
- 4.1.4.Challenges

5.Market variable and outlook

5.1.SWOT Analysis
- 5.1.1.Strengths
- 5.1.2.Weaknesses
- 5.1.3.Opportunities
- 5.1.4.Threats
5.2.PESTEL Analysis
- 5.2.1.Political Landscape
- 5.2.2.Economic Landscape
- 5.2.3.Social Landscape
- 5.2.4.Technological Landscape
- 5.2.5.Environmental Landscape
- 5.2.6.Legal Landscape
5.3.PORTER's Five Forces
- 5.3.1.Bargaining power of suppliers
- 5.3.2.Bargaining power of buyers
- 5.3.3.Threat of Substitute
- 5.3.4.Threat of new entrant
- 5.3.5.Competitive rivalry
5.4.Heat Map Analysis

6.Competitive Landscape

6.1.Global Virtual Clinical Trials Market Manufacturing Base Distribution, Sales Area, Product Type
6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Virtual Clinical Trials Market

7.Global Virtual Clinical Trials Market, By Study Design (USD Million) 2021-2034

7.1.Interventional
7.2.Observational
7.3.Expanded Access

8.Global Virtual Clinical Trials Market, By Indication (USD Million) 2021-2034

8.1.CNS
8.2.Autoimmune/Inflammation
8.3.Cardiovascular Disease
8.4.Metabolic/Endocrinology
8.5.Infectious Disease
8.6.Oncology
8.7.Genitourinary
8.8.Ophthalmology
8.9.Others

9.Global Virtual Clinical Trials Market, By Phase (USD Million) 2021-2034

9.1.Phase I
9.2.Phase II
9.3.Phase III
9.4.Phase IV

10.Global Virtual Clinical Trials Market, (USD Million) 2021-2034

10.1.Global Virtual Clinical Trials Market Size and Market Share

11.Global Virtual Clinical Trials Market, By Region, (USD Million) 2021-2034

11.1.Asia-Pacific
- 11.1.1.Australia
- 11.1.2.China
- 11.1.3.India
- 11.1.4.Japan
- 11.1.5.South Korea
- 11.1.6.Rest of Asia-Pacific
11.2.Europe
- 11.2.1.France
- 11.2.2.Germany
- 11.2.3.Italy
- 11.2.4.Spain
- 11.2.5.United Kingdom
- 11.2.6.Rest of Europe
11.3.Middle East and Africa
- 11.3.1.Kingdom of Saudi Arabia
- 11.3.2.United Arab Emirates
- 11.3.3.Qatar
- 11.3.4.South Africa
- 11.3.5.Egypt
- 11.3.6.Morocco
- 11.3.7.Nigeria
- 11.3.8.Rest of Middle-East and Africa
11.4.North America
- 11.4.1.Canada
- 11.4.2.Mexico
- 11.4.3.United States
11.5.Latin America
- 11.5.1.Argentina
- 11.5.2.Brazil
- 11.5.3.Rest of Latin America

12.Company Profile

12.1.ICON, plc
- 12.1.1.Company details
- 12.1.2.Financial outlook
- 12.1.3.Product summary
- 12.1.4.Recent developments
12.2.Parexel International Corporation
- 12.2.1.Company details
- 12.2.2.Financial outlook
- 12.2.3.Product summary
- 12.2.4.Recent developments
12.3.IQVIA
- 12.3.1.Company details
- 12.3.2.Financial outlook
- 12.3.3.Product summary
- 12.3.4.Recent developments
12.4.Covance
- 12.4.1.Company details
- 12.4.2.Financial outlook
- 12.4.3.Product summary
- 12.4.4.Recent developments
12.5.PRA Health Sciences
- 12.5.1.Company details
- 12.5.2.Financial outlook
- 12.5.3.Product summary
- 12.5.4.Recent developments
12.6.LEO Innovation Lab
- 12.6.1.Company details
- 12.6.2.Financial outlook
- 12.6.3.Product summary
- 12.6.4.Recent developments
12.7.Medidata
- 12.7.1.Company details
- 12.7.2.Financial outlook
- 12.7.3.Product summary
- 12.7.4.Recent developments
12.8.Oracle
- 12.8.1.Company details
- 12.8.2.Financial outlook
- 12.8.3.Product summary
- 12.8.4.Recent developments
12.9.CRF Health
- 12.9.1.Company details
- 12.9.2.Financial outlook
- 12.9.3.Product summary
- 12.9.4.Recent developments
12.10.Clinical Ink
- 12.10.1.Company details
- 12.10.2.Financial outlook
- 12.10.3.Product summary
- 12.10.4.Recent developments
12.11.Medable, Inc
- 12.11.1.Company details
- 12.11.2.Financial outlook
- 12.11.3.Product summary
- 12.11.4.Recent developments
12.12.Signant Health
- 12.12.1.Company details
- 12.12.2.Financial outlook
- 12.12.3.Product summary
- 12.12.4.Recent developments
12.13.Others